Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blarcamesine - Anavex Life Sciences

Drug Profile

Blarcamesine - Anavex Life Sciences

Alternative Names: AE-37 hydrochloride; ANA001-HCl; ANAVEX 2-73; Blarcamesine hydrochloride

Latest Information Update: 16 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anavex Life Sciences
  • Developer ABX-CRO; Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
  • Class Antidementias; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Furans; Neuroprotectants; Neuropsychotherapeutics; Nootropics; Small molecules
  • Mechanism of Action Muscarinic receptor modulators; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy; Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease; Rett syndrome
  • Phase II Parkinson's disease
  • Phase I Epilepsy
  • Preclinical Angelman syndrome; Fragile X syndrome

Most Recent Events

  • 12 Apr 2021 Independent Data Safety Monitoring Board completes interim safety data review for the phase II/III trials
  • 18 Mar 2021 Efficacy data from phase IIa ANAVEX2-73-002 trial in Alzheimer's disease released by Anavex Life Sciences
  • 16 Mar 2021 Efficacy data from phase IIa extension ANAVEX2-73-003 trial in Alzheimer's disease released by Anavex Life Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top